PLX Stock Summary and Trading Ideas (Protalix Biotherapeutics (De) | AMEX:PLX)

Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.

Protalix Biotherapeutics (De) trades on the AMEX stock market under the symbol PLX.

As of September 23, 2026, PLX stock price declined to $2.79 with 430,087 million shares trading.

PLX has a beta of 1.27, meaning it tends to be more sensitive to market movements. PLX has a correlation of 0.05 to the broad based SPY ETF.

PLX has a market cap of $224.79 million. This is considered a Small Cap stock.

Last quarter Protalix Biotherapeutics (De) reported $20 million in Revenue and $.05 earnings per share. This beat revenue expectation by $7 million and exceeded earnings estimates by $.06.

In the last 3 years, PLX traded as high as $3.19 and as low as $.82.

The top ETF exchange traded funds that PLX belongs to (by Net Assets): VTWO, DFAS, BUSM, DFMC, EES.

PLX has outperformed the market in the last year with a price return of +36.8% while the SPY ETF gained +16.3%. PLX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +29.2% and +5.3%, respectively, while the SPY returned +3.4% and +0.5%, respectively.

PLX support price is $2.77 and resistance is $2.91 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PLX shares will trade within this expected range on the day.